Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

被引：8
|
作者：
Stein, Alexander
Binder, Mascha
Al-Batran, Salah-Eddin
Hinke, Axel
Waberer, Lisa
Goekkurt, Eray
Meyer, Tobias
Statovci, Donjete
Depenbusch, Reinhard
Riera-Knorrenschild, Jorge
Lorenzen, Sylvie
Ettrich, Thomas Jens
Doerfel, Steffen
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Hamburg Eppendorf, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] UCT Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[4] CCRC, Dusseldorf, Germany
[5] Krankenhaus Nordwest IKF, Frankfurt, Germany
[6] Univ Canc Ctr Hamburg, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] AIO Studien GmbH, Berlin, Germany
[8] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[9] Universitatsklinikum, Giessen, Germany
[10] Tech Univ Munich, Dept Internal Med Hematol Med Oncol 3, Klin Rechts Isar, Munich, Germany
[11] Ulm Univ Hosp, Ulm, Germany
[12] Onkozentrum Dresden, Dresden, Germany
[13] Hamatologisch Onkolog Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3561
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3561
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF CETUXIMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A PHASE II STUDY
    Barroso, S.
    Sanches, E.
    Ferreira, J.
    Passos, M.
    Sa, A.
    Nabico, R.
    SottoMayor, C.
    Santo, Espirito J.
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2009, 20 : 65 - 65
  • [42] Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
    Barroso, S. A.
    Sanches, E.
    Ferreira, M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
    Martinelli, E.
    Troiani, T.
    Cardone, C.
    Ciardiello, D.
    Zanaletti, N.
    Borrelli, C.
    Terminiello, M.
    Avallone, A.
    Falcone, A.
    Maiello, E.
    Bordonaro, R.
    Santini, D.
    Garufi, C.
    Pietrantonio, F.
    Pinto, C.
    Santabarbara, G.
    Normanno, N.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
    Troiani, Teresa
    Martinelli, Erika
    Ciardiello, Davide
    Zanaletti, Nicoletta
    Cardone, Claudia
    Borrelli, Carola
    Avallone, Antonio
    Falcone, Alfredo
    Maiello, Evaristo
    Bordonaro, Roberto
    Santini, Daniele
    Garufi, Carlo
    De Braud, Filippo G.
    Pinto, Carmine
    Gridelli, Cesare
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [45] A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer
    Redman, J.
    Gandhy, S.
    Gatti-Mays, M.
    Sater, H. Abdul
    Tsai, Y.
    Donahue, R.
    Cordes, L.
    Steinberg, S.
    Marte, J.
    McMahon, S.
    Madan, R.
    Karzai, F.
    Bilusic, M.
    Rabizadeh, S.
    Lee, J.
    Soon-Shiong, P.
    Kim, S.
    Marshall, J.
    Weinberg, B.
    Schlom, J.
    Gulley, J.
    Strauss, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S227 - S227
  • [46] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
  • [47] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [48] Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
    Kondo, Ken
    Kotake, Masanori
    Doden, Kenji
    Munemoto, Yoshinori
    Kobayashi, Kenji
    Nishimura, Genichi
    Omote, Kazuhiko
    Sakamoto, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
  • [50] A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer
    Sym, Sun Jin
    Hong, Junsik
    Jung, Minkyu
    Koo, Yang Seo
    Park, Yeon Ho
    Kim, Koen Kook
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Shin, Dongbok
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345